Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ImmunoGen Inc

+ Add to Watchlist

IMGN:US

8.9900 USD 0.0300 0.33%

As of 11:12:20 ET on 05/29/2015.

Snapshot for ImmunoGen Inc (IMGN)

Open: 9.0100 Day's Range: 8.9500 - 9.1700 Volume: 136,994
Previous Close: 9.0200 52wk Range: 5.3432 - 13.7800 1-Yr Rtn: -23.86%

Stock Chart for IMGN

No chart data available.
  • IMGN:US 8.9900
  • 1D
  • 1M
  • 1Y
9.0200
Interactive IMGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for IMGN

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.6598
Est. EPS (USD) (06/2015) -0.6780
Est. PEG Ratio -
Market Cap (M USD) 777.39
Shares Outstanding (M) 86.19
30 Day Average Volume 1,340,515
Price/Book (mrq) 12.9482
Price/Sale (ttm) 9.8490
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for IMGN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for IMGN

ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.

Daniel M Junius "Dan"President/CEODavid B Johnston "Dave"Exec VP/CFO/Treasurer
Sandra E PooleSenior VP:Technical OperationsCharles Q Morris "Charlie"Exec VP/Chief Development Officer
More Company Profile & Key Executives for IMGN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil